From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer
PUBLISHED: 5:26 PM, WED JUNE 5, 2013
Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Hear financial expert and registered nurse Mary Ann Cagle discuss the financial burden of cancer, often a result of expensive treatments, appointments, and diagnostic tests. Learn where to look for possible financial support.